Methylenetetrahydrofolate reductase gene polymorphism and serum homocysteine levels in nonalcoholic fatty liver disease

Annals of Nutrition and Metabolism

Volumn 63, Issue 3, 2013, Pages 193-199

  Franco Brochado, Maria José ^a   Domenici, Fernanda Aparecida ^a   Candolo Martinelli, Ana De Lourdes ^b   Zucoloto, Sergio ^a   De Carvalho Da Cunha, Selma Freire ^a   Vannucchi, Helio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Pediatric Gastroenterology Division   (Brazil)

Author keywords

Homocysteine; Methylenetetrahydrofolate reductase; Nonalcoholic fatty liver disease; Polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; BLOOD LEVEL; BRAZILIAN; DISEASE SEVERITY; GENE; GENOTYPE; HISTOPATHOLOGY; HUMAN TISSUE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE;

ADULT; ANTHROPOMETRY; BRAZIL; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84898483130     PISSN: 02506807     EISSN: 14219697     Source Type: Journal    
DOI: 10.1159/000353139     Document Type: Article

References (49)

1. Fabbrini E, Sullivan S, Klein S: Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-689.
2. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
4. Machado M, Marques-Vidal P, Cortez-Pinto H: Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600-606.
5. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-1219.
6. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L: Molecular mechanisms involved in NAFLD progression. J Mol Med 2009; 87: 679-695.
7. Rolo AP, Teodoro JS, Palmeira CM: Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012; 52: 59-69.
8. Mason JB: Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism. J Nutr 2003; 133(suppl 3):941S-947S.
9. Gulsen M, Yesilova Z, Bagci S, Uygun A, Ozcan A, Ercin CN, Erdil A, Sanisoglu SY, Cakir E, Ates Y, Erbil MK, Karaeren N, Dagalp K: Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-Alcoholic fatty liver disease. J Gastroenterol Hepatol 2005; 20: 1448-1455.
10. Polyzos SA, Kountouras J, Patsiaoura K, Katsiki E, Zafeiriadou E, Deretzi G, Zavos C, Gavalas E, Katsinelos P, Mane V, Slavakis A: Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Ann Hepatol 2012; 11: 68-76.
11. Ventura P, Rosa MC, Abbati G, Marchini S, Grandone E, Vergura P, Tremosini S, Zeneroli ML: Hyperhomocysteinaemia in chronic liver diseases: role of disease stage, vitamin status and methylenetetrahydrofolate reductase genetics. Liver Int 2005; 25: 49-56.
12. Ji C, Kaplowitz N: Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury. World J Gastroenterol 2004; 10: 1699-1708.
13. Woo CW, Prathapasinghe GA, Siow YL, O K: Hyperhomocysteinemia induces liver injury in rat: protective effect of folic acid supplementation. Biochim Biophys Acta 2006; 1762: 656-665.
14. Ji C, Kaplowitz N: Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 2003; 124: 1488-1499.
15. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, Zhou J, Maeda N, Krisans SK, Malinow MR, Austin RC: Homocysteineinduced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001; 107: 1263-1273.
16. Molloy AM: Folate and homocysteine interrelationships including genetics of the relevant enzymes. Curr Opin Lipidol 2004; 15: 49-57.
17. Kim YI: 5,10-methylenetetrahydrofolate reductase polymorphisms and pharmacogenetics: a new role of single nucleotide polymorphisms in the folate metabolic pathway in human health and disease. Nutr Rev 2005; 63: 398-407.
18. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
19. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ: A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-Tube defects? Am J Hum Genet 1998; 62: 1044-1051.
20. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R, Blom HJ: Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070-1071.
21. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G: Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-421.
22. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, Olivieri O, Jacques PF, Rosenberg IH, Corrocher R, Selhub J: A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002; 99: 5606-5611.
23. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
24. Di Rosa M, Malaguarnera L: Genetic variants in candidate genes influencing NAFLD progression. J Mol Med (Berl) 2012; 90: 105-118.
25. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA: Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820.
26. WHO: Obesity: preventing and managing the global epidemic -report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:i-xii, 1-253.
27. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
28. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001; 285: 2486-2497.
29. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
31. Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, Carvalho FM, de Freitas LA, Barreto D, Gouveia L, Landeiro L: Non-Alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol 2005; 17: 837-841.
32. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
33. Hanson NQ, Aras O, Yang F, Tsai MY: C677t and a1298c polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 2001; 47: 661-666.
34. Serin E, Guclu M, Atac FB, Verdi H, Kayaselcuk F, Ozer B, Bilezikci B, Yilmaz U: Methylenetetrahydrofolate reductase c677t mutation and nonalcoholic fatty liver disease. Dig Dis Sci 2007; 52: 1183-1186.
35. Sazci A, Ergul E, Tuncer N, Akpinar G, Kara I: Methylenetetrahydrofolate reductase gene polymorphisms are associated with ischemic and hemorrhagic stroke: dual effect of MTHFR polymorphisms C677T and A1298C. Brain Res Bull 2006; 71: 45-50.
36. Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S: C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis 1998; 136: 347-354.
37. D'Angelo A, Mazzola G, Fermo I: Gene-gene and gene-environment interactions in mild hyperhomocysteinemia. Pathophysiol Haemost Thromb 2003; 33: 337-341.
38. Kluijtmans LA, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, Strain JJ, McPartlin J, Scott JM, Whitehead AS: Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101: 2483-2488.
39. Chango A, Potier De Courcy G, Boisson F, Guilland JC, Barbe F, Perrin MO, Christides JP, Rabhi K, Pfister M, Galan P, Hercberg S, Nicolas JP: 5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) cohort. Br J Nutr 2000; 84: 891-896.
40. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
41. Lievers KJ, Boers GH, Verhoef P, den Heijer M, Kluijtmans LA, van der Put NM, Trijbels FJ, Blom HJ: A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med (Berl) 2001; 79: 522-528.
42. Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, Eckfeldt JH, Rozen R: The 1298A → C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001; 156: 409-415.
43. Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, Mendel M, Kidron M, Bar-On H: A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr 1999; 129: 1656-1661.
44. Arruda VR, Siqueira LH, Goncalves MS, von Zuben PM, Soares MC, Menezes R, Annichino-Bizzacchi JM, Costa FF: Prevalence of the mutation C677 → T in the methylene tetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet 1998; 78: 332-335.
45. Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA: Analysis of the 677 C → T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998; 79: 119-121.
46. Carvalho Barbosa RD, Menezes DC, Freire TF, Sales DC, Alencar VH, Rabenhorst SH: Associations of polymorphisms of folate cycle enzymes and risk of breast cancer in a Brazilian population are age dependent. Mol Biol Rep 2012; 39: 4899-4907.
47. Garcia-Tevijano ER, Berasain C, Rodriguez JA, Corrales FJ, Arias R, Martin-Duce A, Caballeria J, Mato JM, Avila MA: Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis. Hypertension 2001; 38: 1217-1221.
48. Polyzos SA, Anastasilakis AD, Efstathiadou Z, Litsas I, Kita M, Panagiotou A, Papatheodorou A, Arsos G, Moralidis E, Barmpalios G, Zafeiriadou E, Triantafillidou E, Makrigiannaki E, Terpos E: Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid. J Bone Miner Metab 2010; 28: 314-319.
49. Sazci A, Ergul E, Aygun C, Akpinar G, Senturk O, Hulagu S: Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). Cell Biochem Funct 2008; 26: 291-296.